Meeting
2023 ASCO Annual Meeting
A multicenter, open-label, single-arm phase 1/2 study to evaluate the safety and efficacy of FCN-159 in pediatric participants with neurofibromatosis type 1.
Authors
Xiaojie Hu
Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China
Xiaojie Hu , JinHu Wang , Wenbin Li , Kang Zeng , Yanling Li , Juan Tao , Zhonghai Guan , Zhuang Kang , Zhongyuan Xu , Changxing Li , Yaohui Ma , Liu Yang , Zhuli Wu , Pu Han , Hongmei Lin , Ben Li , Ai-Min Hui , Xingli Wang , Xiaoxi Lin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT04954001
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 10023)
DOI
10.1200/JCO.2023.41.16_suppl.10023
Abstract #
10023
Poster Bd #
329
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase 1/2 trial of lurbinectedin (L) in combination with pembrolizumab (P) in relapsed small cell lung cancer (SCLC): The LUPER study.
First Author: Antonio Calles
Poster
2024 ASCO Annual Meeting
QUIC: Phase 2 study of gemcitabine, cisplatin, quemliclustat (AB680), and zimberelimab (AB122) during first-line treatment of advanced biliary tract cancers (BTC)—Big Ten Cancer Research Consortium study BTCRC-GI22-564.
First Author: John Ebben
Poster
2023 ASCO Annual Meeting
Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a study.
First Author: Kathleen N. Moore
Poster
2023 ASCO Annual Meeting
A multicenter, open-label, single-arm, phase 1 dose-escalation and phase 2 dose-expansion study to evaluate the safety, tolerability, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1.
First Author: Xiaojie Hu